Biotechnology Value Fund L P's Form 4 filing
Repare Therapeutics Inc. (RPTX) · filed Jun 6, 2022
- Accession no.
- 0000921895-22-001916
- Filed
- Jun 6, 2022, 6:14 PM ET
- Trade date
- Jun 2-6, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 9 non-derivative transactions and 0 derivative transactions. Open-market purchases total $21.9M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Biotechnology Value Fund L PCIK 0000918923 | 10% Owner |
| BVF Partners L PCIK 0001055947 | 10% Owner |
| BVF IncCIK 0001056807 | 10% Owner |
| Biotechnology Value Fund II LPCIK 0001102444 | Other: See Explanation of Responses |
| Lampert Mark NCIK 0001233840 | 10% Owner |
| Biotechnology Value Trading Fund OS LPCIK 0001660683 | Other: See Explanation of Responses |
| BVF Partners OS Ltd.CIK 0001660684 | Other: See Explanation of Responses |
| BVF I GP LLCCIK 0001803805 | 10% Owner |
| BVF II GP LLCCIK 0001803806 | Other: See Explanation of Responses |
| BVF GP Holdings LLCCIK 0001803809 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 2, 2022 | Common Shares, no par value | PPurchaseAcquired | +660,654 | $11.68 | +$7,718,024.29 | 4,011,604 | Direct | |
| Jun 3, 2022 | Common Shares, no par value | PPurchaseAcquired | +353,344 | $12.29 | +$4,341,184.38 | 4,364,948 | Direct | |
| Jun 6, 2022 | Common Shares, no par value | PPurchaseAcquired | +3,809 | $13.21 | +$50,323.75 | 4,368,757 | Direct | |
| Jun 2, 2022 | Common Shares, no par value | PPurchaseAcquired | +464,235 | $11.68 | +$5,423,378.96 | 2,969,742 | Direct | |
| Jun 3, 2022 | Common Shares, no par value | PPurchaseAcquired | +258,797 | $12.29 | +$3,179,579.94 | 3,228,539 | Direct | |
| Jun 6, 2022 | Common Shares, no par value | PPurchaseAcquired | +3,040 | $13.21 | +$40,163.87 | 3,231,579 | Direct | |
| Jun 2, 2022 | Common Shares, no par value | PPurchaseAcquired | +61,156 | $11.68 | +$714,448.85 | 374,513 | Direct | |
| Jun 3, 2022 | Common Shares, no par value | PPurchaseAcquired | +31,903 | $12.29 | +$391,960.26 | 406,416 | Direct | |
| Jun 6, 2022 | Common Shares, no par value | PPurchaseAcquired | +20 | $13.21 | +$264.24 | 406,436 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.